文献速递心脑血管急症消化、代谢与肾脏急症

围绝经期血管舒缩症状女性的绝经激素治疗与心血管风险

Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women With Vasomotor Symptoms.
PubMed 文献 · JAMA Intern Med · 2026-09-08
一句话结论有血管舒缩症状的围绝经期或绝经后近期女性启动MHT与CVD风险降低相关(aHR 0.78),但证据为观察性,不能用于CVD预防。

该研究基于SWAN多中心纵向队列(1997-2017),采用目标试验模拟方法,纳入2737名有血管舒缩症状、无CVD且未用过MHT的女性,其中755人启动MHT。随访20年间发生224例致死和非致死性CVD事件。启动MHT者CVD风险降低22%(aHR 0.78,95%CI 0.62-0.98),绝经10年内启动者获益更明显(aHR 0.73),黑人女性获益显著(aHR 0.51)。但作者强调残留混杂可能,结果不一致,不应据此用MHT预防CVD。

要点

  • 有血管舒缩症状的围绝经期或绝经后近期女性,启动MHT与CVD事件风险降低相关(aHR 0.78,95%CI 0.62-0.98)。
  • 该研究为观察性队列的目标试验模拟,存在残留混杂,结果不能用于支持MHT预防CVD。
  • MHT使用定义为全身雌激素联合或不联合孕激素,经药物容器核实。

适用人群与场景

  • 围绝经期和绝经后近期女性,自我报告过去2周内有任何血管舒缩症状(潮热和/或盗汗),无CVD,且既往未使用MHT。

诊断标准与关键阈值

  • 血管舒缩症状定义为自我报告过去2周内出现潮热和/或盗汗。
  • CVD事件包括心肌梗死、卒中、心力衰竭和血运重建,为自我报告;CVD相关死亡来自死亡证明。
  • MHT暴露定义为使用全身雌激素联合或不联合孕激素,经药物容器核实。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:基于SWAN队列(1997-2017)的目标试验模拟,多中心、多民族纵向研究。
  • 样本量:2737名有血管舒缩症状的女性,其中755人启动MHT(平均年龄53.7岁,SD 4.6),随访20年发生224例致死和非致死性CVD事件。
  • 主要终点:启动MHT vs 未启动的CVD事件校正风险比(aHR)为0.78(95%CI 0.62-0.98)。

证据类型、等级与局限

  • 证据类型:观察性队列研究的目标试验模拟(非随机化),原文未给出证据等级或推荐强度。
  • 局限:原文指出所有估计值因潜在残留混杂而需谨慎解读;心血管获益不一致,需考虑总体风险-获益平衡,不应据此支持MHT用于CVD预防。

对床旁实践的改变

  • 对于有血管舒缩症状的围绝经期或绝经后近期女性,MHT启动与CVD风险降低相关,但该证据来自观察性研究,不能改变现有实践用于CVD预防。
  • 临床决策仍需基于总体风险-获益平衡,原文明确不推荐将MHT用于CVD预防。
  • 启动MHT时应考虑绝经时间(10年内可能获益更明显)和种族差异(黑人女性可能获益),但需警惕残留混杂。

指南或共识出处

  • 原文未提及指南或共识名称;研究数据来自Study of Women's Health Across the Nation (SWAN)队列。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Vasomotor symptoms in perimenopause are associated with increased future cardiovascular (CVD) risk. Most clinical trials on menopausal hormone therapy (MHT) and CVD risk have focused on postmenopausal women, with limited study of the perimenopausal period when hormonal fluctuations and symptoms are greatest. Moreover, these trials were not designed to evaluate CVD risk with MHT among women with vasomotor symptoms.

OBJECTIVE: To estimate the effect of MHT on CVD risk among perimenopausal and recently postmenopausal women with vasomotor symptoms and assess the extent to which timing of MHT use relative to menopause and race and ethnicity modify this effect.

DESIGN, SETTING, AND PARTICIPANTS: Cohort data from the Study of Women's Health Across the Nation (SWAN, 1997-2017)-a multiethnic, multicenter, longitudinal study of the menopause transition-were used to emulate a sequence of target trials. Eligible participants were women who self-reported any vasomotor symptoms (ie, hot flashes and/or night sweats over the past 2 weeks) and who were CVD-free, with no prior MHT use. Data were analyzed from January 2023 to December 2025.

EXPOSURE: MHT use (systemic estrogen with/without progestogens, verified from medication containers).

MAIN OUTCOMES AND MEASURES: CVD events (myocardial infarction, stroke, heart failure, and revascularization) were self-reported. CVD-related death was recorded from death certificates.

RESULTS: Of 2737 women who reported any vasomotor symptoms, 755 initiated MHT (mean [SD] age, 53.7 [4.6] years) over the 20-year follow-up period, during which 224 fatal and nonfatal CVD events occurred. Overall, the estimated adjusted hazard ratio (aHR) of CVD events for MHT initiation vs noninitiation was 0.78 (95% CI, 0.62-0.98). The estimated aHR was 0.73 (95% CI, 0.58-0.93) and 1.53 (95% CI, 0.66-3.52) among women initiating MHT 10 or fewer years vs more than 10 years from the onset of menopause, respectively (P value for interaction: .02). Race and ethnicity modified the MHT initiation effect, with Black women showing protective effect (aHR, 0.51; 95% CI, 0.33-0.81), while no clear effects were observed in White women or women of other races (P value for interaction = .007).

CONCLUSIONS AND RELEVANCE: The presented results are pooled from all target trials and found that MHT initiation during perimenopause or recently postmenopausal women with vasomotor symptoms was estimated to reduce CVD risk by 22%. Benefits were more pronounced in Black women and women who initiated MHT within 10 years of menopause onset. However, all estimates warrant caution given the potential for residual confounding. Given the inconsistency of the cardiovascular benefits and the need to consider overall risk-benefit balance, these findings should not be used to support MHT for CVD prevention.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Wang Z, Swanson SA, Brooks MM, et al. Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women With Vasomotor Symptoms. JAMA Intern Med. 2026. PMID: 42709460. doi:10.1001/jamainternmed.2026.2922

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。